Open Cancer Trials
All Open Trials | Open Cancer Trials | Open HIV Trials
| Title | Trial ID# | Disease Indication | Cell-Biologic Product | Principal Investigator |
|---|---|---|---|---|
| Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia (NCT02650414) | 15CT055 | Pediatric ALL | Autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) | Stephan Grupp, MD, PhD |
| Phase 2 Study of Humanized CD19-directed Chimeric Antigen Receptor-modified T cells (huCART19) for Very High-Risk Subsets of B cell Acute Lymphoblastic Leukemia (B-ALL) (NCT03792633) | 18CT014 | Pediatric ALL | huCART19 | Shannon Maude, MD |
| Phase 1 Study of Human Chimeric Antigen Receptor Modified T Cells in Patients with Mesothelin Expressing Cancers (NCT03054298) | UPCC02916 | Mesothelin expressing cancers | huCART-MESO | Janos Tanyi, MD, PhD |
| Phase 1 Clinical Trial of Adoptive Transfer of Autologous Folate Receptor – Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03585764) | UPCC03818 | Ovarian Cancer | Powell Alpha Folate Receptor MOV19 | Dr. Payal Shah |
| Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (huCART-meso) Administered in Combination with VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian Cancer (NCT05057715) | UPCC03821 | Ovarian and Pancreatic Cancers | huCART-MESO + VCN-01 | Janos Tanyi, MD, PhD |
| Pilot Study of Mature Dendritic Cell Vaccination Against Mutated KRAS in Patients With Resectable Pancreatic Cancer (NCT03592888) | UPCC04218 | Pancreatic Cancer | Dendritic cells | Mark O’Hara, MD |
| Phase I Study of EGFRvIII-Directed CAR T cells combined with PD-1 Inhibition in Patients with Newly Diagnosed, MGMT-Unmethylated Glioblastoma (NCT03726515) | UPCC13318 | Glioblastoma | EGFRvIII-Directed CAR T cells | Donald O'Rourke |
| Phase 1 Study of Human Chimeric Antigen Receptor Modified T Cells in Patients with Pancreatic Cancer (NCT03323944) | UPCC14217 | Pancreatic Cancer | huCART-meso cells | Mark O'Hara, MD |
| Pilot Study of Mature Dendritic Cell Vaccination for Resected Hypermutated Colorectal Cancer (NCT03730948) | UPCC16218 | Colorectal Cancer | Dendritic Cells | Kim Reiss-Binder, MD |
| Mature Dendritic Cell Vaccination Against Mutated Antigens in Patients With Advanced Melanoma (NCT03092453) | UPCC17616 | Melanoma | Pulsed Dendritic Cells | Gerald Linette, MD |
| Phase 1 Trial of autologous T cells engineered to express NY-ESO-1 and gene edited to eliminate endogenous TCR and PD-1 (NCT03399448) | UPCC25416 | Sarcoma, Melanoma, Myeloma | NY-ESO TCR/CRISPR | Edward Stadtmauer, MD |
| Phase 1 study of PSMA-TGFBRDN CAR modified T cells in patients with advanced castrate resistant prostate cancer (NCT03089203) | UPCC32816 | Prostate Cancer | PSMA-dnTGFbR CAR | Naomi Haas, MD |
| Phase 2 Study of CD19-directed Chimeric Antigen Receptor-modified T cells (CART19) for Adult Patients with Minimal Residual Disease During Upfront Treatment for Acute Lymphoblastic Leukemia (NCT02935543) | UPCC39416 | Acute Lymphoblastic Leukemia | mCART19 (for ALL MRD+) | Noelle Frey, MD |
| Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Pediatric Subjects With Refractory or Relapsed Acute Myeloid Leukemia (NCT04678336) | 19CT011 | Acute Myeloid Leukemia | CART123 | Richard Aplenc, MD, PhD, MSCE |
| Phase 2 Trial of CD19-Directed Chimeric Antigen Receptor CD19 Redirected Autologous T cells (CART19) for Orphan Indications of Pediatric B cell Acute Lymphoblastic Leukemia (B-ALL) (NCT04276870) | 19CT023 | Pediatric ALL, Orphan Indications | murine CART19 | Amanda DiNofia, MD |
| Phase I Trial of huCART19-IL18 Cells in Patients With Relapsed or Refractory CD19+ Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (NCT04684563) | UPCC15420 | NHL, CLL | huCART19-IL18 | Jakub Svoboda, MD |
| Phase I Trial of Programmed Allogeneic CRISPR-edited T Cells (PACE) Gene Edited to Eliminate Endogenous TCR, HLA-class I and HLA-class II and Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma (NCT05037669) | UPCC27419 | ALL, NHL, CLL | PACE CART19 | Noelle Frey, MD |
| Phase I Trial of GFRa4 CAR T Cells in Adult Patients with Recurrent or Metastatic Medullary Thyroid Cancer (NCT04877613) | UPCC12320 | Medullary Thyroid Cancer | CART-GFRa4 | Roger Cohen, MD |
Contact Us
Clinical Cell and Vaccine Production Facility (CVPF)
Center for Advanced Cellular Therapies
9th Floor SPE/South Tower, Bldg. 421
3400 Civic Center Boulevard
Philadelphia, PA 19104
